We systematically interrogated the Cancer Therapeutics Response Portal datasets, and found that E2F4 expression correlated with resistance to ferroptosis inducers ((RSL3, ML210 and ML162, which inhibit GPX4 activity) (Fig. 5K). This evidence concerns the gene GPX4 and cancer.